Clinical Trials
28 trialsUC-GlioFET
University of California, San Francisco
EVA DOPA
Centre Hospitalier Universitaire de Nīmes
FDG PET/CT in Monitoring Very Early Therapy Response in Patients With Glioblastoma
Jonsson Comprehensive Cancer Center
Fluorine F 18 Fluorodopa-Labeled PET Scan in Planning Surgery and Radiation Therapy in Treating Patients With Newly Diagnosed High- or Low-Grade Malignant Glioma
Mayo Clinic
Spectroscopic MRI-Guided Radiation Therapy Planning in Glioblastoma
Emory University
18F-DOPA-PET/MRI Scan in Imaging Elderly Patients With Newly Diagnosed Grade IV Malignant Glioma or Glioblastoma During Planning for a Short Course of Proton Beam Radiation Therapy
Mayo Clinic
18F-FDG PET and Osimertinib in Evaluating Glucose Utilization in Patients with EGFR Activated Recurrent Glioblastoma
Jonsson Comprehensive Cancer Center
Non-Contrast Perfusion Using Arterial Spin Labeled MR Imaging for Assessment of Therapy Response in Glioblastoma
University of Texas Southwestern Medical Center
F18 Fluciclovine PET/CT in Assessing Tumor Volume and Radiation Therapy Response in Patients With Glioblastoma Undergoing Surgery
M.D. Anderson Cancer Center
Cediranib, Temozolomide, and Radiation Therapy in Treating Patients With Newly Diagnosed Glioblastoma
National Cancer Institute (NCI)
BRITER
Brighton and Sussex University Hospitals NHS Trust
Monitoring Anti-angiogenic Therapy in Brain Tumors by Advanced MRI
Massachusetts General Hospital
Steady State Blood Volume Maps Using Ferumoxytol Non-stoichiometric Magnetite MRI in Imaging Patients With Glioblastoma
OHSU Knight Cancer Institute
PET/CT Imaging of Malignant Brain Tumors With 124I-NM404
University of Wisconsin, Madison
Border Zone Stereotactic Radiosurgery With Bevacizumab in Patients With Glioblastoma Multiforme
University of Pittsburgh
MRI and PET/FMISO In Assessing Tumor Hypoxia in Patients With Newly Diagnosed Glioblastoma Multiforme
National Cancer Institute (NCI)
Positron Emission Tomography Using Fluorothymidine F 18 in Finding Recurrent Disease in Patients With Gliomas
University of Washington
Magnetic Resonance Spectroscopy Imaging in Predicting Response to Vorinostat and Temozolomide in Patients With Recurrent or Progressive Glioblastoma
National Cancer Institute (NCI)
Phase I Study of Cellular Immunotherapy for Recurrent/Refractory Malignant Glioma Using Intratumoral Infusions of GRm13Z40-2, An Allogeneic CD8+ Cytolitic T-Cell Line Genetically Modified to Express the IL 13-Zetakine and HyTK and to be Resistant to Glucocorticoids, in Combination With Interleukin-2
City of Hope Medical Center
Imaging Biomarkers of Tissue Microstructure and Vasculature as Predictors of Glioblastoma Multiforme
Medical University of South Carolina
Lapatinib in Treating Young Patients With Recurrent or Refractory Central Nervous System Tumors
National Cancer Institute (NCI)
Magnetic Resonance Imaging and Magnetic Resonance Spectroscopic Imaging in Evaluating Patients Who Are Undergoing Treatment for Gliomas
University of California, San Francisco
Motexafin Gadolinium With MRI-Guided Surgery in Treating Patients With High-Grade Gliomas
National Cancer Institute (NCI)
Radiation Therapy and Gadolinium Texaphyrin in Treating Patients With Supratentorial Glioblastoma Multiforme
National Cancer Institute (NCI)
Magnetic Resonance Imaging in Determining Extent of Cancer in Patients With Newly Diagnosed Glioma
Jonsson Comprehensive Cancer Center
Tumor DNA and MRI/CT Scan Findings in Patients With Grade III or Grade IV Malignant Glioma
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Measuring Non-Enhancing Glioblastoma Progression
M.D. Anderson Cancer Center
Thalidomide and Temozolomide or Camptothecin-11 (CPT-11) in Patients With Gliomas
M.D. Anderson Cancer Center